788 related articles for article (PubMed ID: 19581278)
21. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
22. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
23. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis.
Toonen EJ; Coenen MJ; Kievit W; Fransen J; Eijsbouts AM; Scheffer H; Radstake TR; Creemers MC; de Rooij DJ; van Riel PL; Franke B; Barrera P
Ann Rheum Dis; 2008 Aug; 67(8):1174-7. PubMed ID: 18385279
[TBL] [Abstract][Full Text] [Related]
24. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2007 Jul; 66(7):921-6. PubMed ID: 17301106
[TBL] [Abstract][Full Text] [Related]
25. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
[TBL] [Abstract][Full Text] [Related]
26. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
Solau-Gervais E; Laxenaire N; Cortet B; Dubucquoi S; Duquesnoy B; Flipo RM
Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
28. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
29. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
[TBL] [Abstract][Full Text] [Related]
30. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
[TBL] [Abstract][Full Text] [Related]
31. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
32. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
Van Doornum S; McColl G; Wicks IP
Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
[TBL] [Abstract][Full Text] [Related]
33. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Vis M; van der Horst AR; Wolbink GJ; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Lems WF; Nurmohamed MT; Aarden L; Hamann D
Ann Rheum Dis; 2009 Apr; 68(4):558-63. PubMed ID: 18445623
[TBL] [Abstract][Full Text] [Related]
34. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G;
J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
36. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
37. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.
Blom M; Kievit W; Kuper HH; Jansen TL; Visser H; den Broeder AA; Brus HL; van de Laar MA; van Riel PL
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1335-41. PubMed ID: 20506128
[TBL] [Abstract][Full Text] [Related]
38. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
39. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
40. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.
Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G;
Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]